PlatformQ Health and Global Genes partner to form the Google of rare diseases

Global Genes and PlatformQ Health are patterning up to develop the Google of rare disease, RareUniversity. With rare diseases affecting 1 in 10 people in the US, and 350 million worldwide, these patients are on a constant search for information and specialists on their condition. The partnership of Global Genes and PlatformQ Health, hopes to bring access to accurate information about an array of rare disease to both patients and clinicians. "Education is at the core of what Global Genes is committed to providing to patients and caregivers. It is a catalyst for success and a driver of change," says Global Genes CEO, Nicole Boice. "In our desire to increase patient impact, we look to other innovators to help us grow to meet the increasing needs of this community. RareUniversity and our partnership with PlatformQ Health will help us meet and exceed these goals. We are honored to be collaborating and continuing to drive value for all of the rare disease stakeholders who need more insights and tools." The online platform, RareUniversity, will be an interactive medical education program where patients and clinicians will have access to information and resources on rare diseases. "Accurate and clinically valid education, including reporting on breakthroughs in research and development, is one of the most valuable tools anyone facing a rare disease can have," says Robert Rosenbloom, CEO of PlatformQ Health. "Together with Global Genes and the organizations they serve, RareUniversity will provide a trusted educational platform to measurably improve the state of rare disease education and advocacy."
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”